Scilex Holding Company (SCLX), an Emerging Growth Company, announced a material definitive agreement (Nov 3, 2025) granting it an exclusive, worldwide license from Datavault AI (DVAI) for proprietary data platforms relevant to the biotech, diagnostic, and therapeutics industries.
Strategic Initiative: SCLX plans to use this DVAI IP, including a key pending patent for tokenizing DNA data, to launch a Biotech Exchange platform (potentially expanding to a full Pharmaceutical Exchange) to tokenize and monetize Real World Assets (RWA) for non-dilutive funding, complementing existing portfolio
...